Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Thapa, HB; Passegger, CA; Fleischhacker, D; Kohl, P; Chen, YC; Kalawong, R; Tam-Amersdorfer, C; Gerstorfer, MR; Strahlhofer, J; Schild-Prüfert, K; Zechner, EL; Blesl, A; Binder, L; Busslinger, GA; Eberl, L; Gorkiewicz, G; Strobl, H; Högenauer, C; Schild, S.
Enrichment of human IgA-coated bacterial vesicles in ulcerative colitis as a driver of inflammation.
Nat Commun. 2025; 16(1): 3995
Doi: 10.1038/s41467-025-59354-5
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Hoegenauer Christoph
- Co-Autor*innen der Med Uni Graz
- Binder Lukas
- Blesl Andreas
- Gorkiewicz Gregor
- Schild Kristina
- Strobl Herbert
- Tam-Amersdorfer Carmen
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The gut microbiome contributes to chronic inflammatory responses in ulcerative colitis (UC), but molecular mechanisms and disease-relevant effectors remain unclear. Here we analyze the pro-inflammatory properties of colonic fluid obtained during colonoscopy from UC and control patients. In patients with UC, we find that the pelletable effector fraction is composed mostly of bacterial extracellular vesicles (BEVs) that exhibit high IgA-levels and incite strong pro-inflammatory responses in IgA receptor-positive (CD89+) immune cells. Biopsy analyses reveal higher infiltration of CD89+ immune cells in the colonic mucosa from patients with UC than control individuals. Further studies show that IgA-coated BEVs, but not host-derived vesicles nor soluble IgA, are potent activators of pro-inflammatory responses in CD89+ cells. IgA-coated BEVs also exacerbate intestinal inflammation in a dextran sodium sulfate colitis model using transgenic mice expressing human CD89. Our data thus implicate a link between IgA-coated BEVs and intestinal inflammation via CD89+ immune cells, and also hint a potential new therapeutic target for UC.